Orthopediatrics Corp (NASDAQ:KIDS) has earned an average recommendation of “Buy” from the six ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $44.25.
KIDS has been the subject of a number of research analyst reports. Needham & Company LLC initiated coverage on Orthopediatrics in a report on Wednesday, June 19th. They issued a “buy” rating and a $53.00 target price for the company. Zacks Investment Research upgraded Orthopediatrics from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a report on Friday. BidaskClub upgraded Orthopediatrics from a “sell” rating to a “hold” rating in a report on Friday, August 2nd. ValuEngine lowered Orthopediatrics from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, BTIG Research restated a “buy” rating and issued a $44.00 target price on shares of Orthopediatrics in a report on Friday, May 10th.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. American Century Companies Inc. purchased a new stake in shares of Orthopediatrics during the fourth quarter worth $3,880,000. Roubaix Capital LLC purchased a new stake in shares of Orthopediatrics during the second quarter worth $3,497,000. Wasatch Advisors Inc. raised its holdings in shares of Orthopediatrics by 28.2% during the second quarter. Wasatch Advisors Inc. now owns 347,598 shares of the company’s stock worth $13,556,000 after acquiring an additional 76,534 shares in the last quarter. Calamos Advisors LLC purchased a new stake in shares of Orthopediatrics during the second quarter worth $2,373,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Orthopediatrics during the second quarter worth $2,055,000. Institutional investors own 48.56% of the company’s stock.
Orthopediatrics (NASDAQ:KIDS) last released its earnings results on Wednesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.05). The business had revenue of $18.20 million during the quarter, compared to analysts’ expectations of $18.44 million. Orthopediatrics had a negative net margin of 15.77% and a negative return on equity of 13.90%. Orthopediatrics’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.21) EPS. Equities analysts anticipate that Orthopediatrics will post -0.45 earnings per share for the current fiscal year.
Orthopediatrics Company Profile
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.
Further Reading: Why is cost of goods sold important?
Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.